Acute Lymphoblastic Leukemia (ALL) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Acute lymphoblastic leukaemia (ALL) affects blood and bone marrow and is characterized by overproduction of immature white blood cells, called lymphoblasts or leukaemic blasts. Acute Lymphoblastic Leukemia (ALL) is an aggressive form of Non-Hodgkin's Lymphoma (NHL), most common among children under 5 years of age. The total incident population of adult acute lymphoblastic leukemia (ALL) in the G7 markets is estimated to be 5173 in 2030 with a CAGR of 0.5%. Standard induction therapy usually consists of a four-drug regimen of vincristine, prednisone, anthracyclines, and cyclophosphamide or L-asparaginase, or a four-drug regimen of vincristine, prednisone, anthracyclines, cyclophosphamide over 4-6 weeks.

Description

Acute lymphoblastic leukaemia (ALL) is a cancer type which affects blood and bone marrow and is characterized by overproduction of immature white blood cells, called lymphoblasts or leukaemic blasts. Acute Lymphoblastic Leukemia (ALL) is an aggressive form of Non-Hodgkin's Lymphoma (NHL), most common among children under 5 years of age. Overall, about 4 of every 10 cases of ALL are in adults. The risk is slightly higher in males than in females, and higher in Caucasians. The risk of ALL increases after 50 years of age and is more likely to be fatal in adults than in children. Adult ALL has historically had a dismal prognosis, with limited treatment options and cure rates less than 40% due to higher-risk disease features and significant chemotherapy-associated toxicity.

Acute Lymphoblastic Leukemia (ALL)- (Epidemiology)

Leukemia in children is most frequently associated with ALL in the US. 17 years old is the median age at diagnosis. ALL is the root cause of 74% of pediatric leukemia cases. Every year, the US reports 6,000 new cases of ALL types. The majority of ALL cases, which have a slight male predominance, affect children under the age of six. About 85% of ALL cases are B-cell-related, while only 15% are T-cell-related. T-ALL makes up about 25% of adult ALL. Adults are more likely to develop acute myeloid leukemia (AML) than ALL, and the estimated 5-year survival rate for AML is 70.8%. The good survival rate is due to the high success rate of curing ALL in children. Death occurs at a median age of 59 years, and the prognosis worsens with age. Italy, the United States, Switzerland, and Costa Rica have the highest rates of ALL.

Acute Lymphoblastic Leukemia (ALL)- Current Market Size & Forecast Trends

The global ALL therapeutics market is valued at $2.5 billion as of 2023. The market is experiencing significant growth due to the adoption of innovative treatments like CAR-T cell therapies, bispecific T-cell engagers (BiTEs), and monoclonal antibodies. With an increasing global incidence and rising investment in R&D, the market is expected to expand at a CAGR of ~6%, reaching approximately $5 billion by 2035.

Standard induction therapy typically involves a four-drug regimen of vincristine, prednisone, anthracyclines, and cyclophosphamide or L-asparaginase, or a four-drug regimen of vincristine, prednisone, anthracyclines, and cyclophosphamide and a five-drug paraginase regimen. Between 65 and 85% of patients who use this method experience complete remission (CR). Based on the success of short-term, high-dose chemotherapy regimens in children, another option is the hyper-CVAD regimen. It also includes dexamethasone and vincristine along with high-dose cytarabine (Ara-C), hyperfractionated cyclophosphamide, and methotrexate. Prednisone, vincristine (Oncovin), methotrexate, and mercaptopurine (Purinol) are used as part of the maintenance phase of treatment (i.e., POMP). Studies have demonstrated that patients with CR disease during the first four weeks of treatment have longer disease-free and overall survival times than patients whose disease has gone into remission after the first four weeks of treatment. The addition of rituximab helped patients with CD20 lymphocytes. The primary endpoint of Morey et. al., study was event-free survival in CD20, Philadelphia chromosome (Ph) negative (Ph-) adults (18 to 59 years old) who were randomly assigned to chemotherapy with or without rituximab. In all treatment phases, 16 to 18 rituximab injections were administered. After a median follow-up of 30 months, the rituximab group's event-free survival was higher than the control group's (hazard ratio, 0.66; 95 % confidence interval, 0.45 to 0.98; P = .04); the estimated rates of event-free survival at 2 years were 65% and 52%, respectively.

Report Highlights

Acute Lymphoblastic Leukemia (ALL)- Current Market Trends

Acute Lymphoblastic Leukemia (ALL)- Current & Forecasted Cases across the G8 Countries

Acute Lymphoblastic Leukemia (ALL)- Market Opportunities and Sales Potential for Agents

Acute Lymphoblastic Leukemia (ALL)- Patient-based Market Forecast to 2035

Acute Lymphoblastic Leukemia (ALL)- Untapped Business Opportunities

Acute Lymphoblastic Leukemia (ALL)- Product Positioning Vis-a-vis Competitors' Products

Acute Lymphoblastic Leukemia (ALL)- KOLs Insight